By Hendra Lukman 
Stanford Medicine scientists have achieved a groundbreaking success in treating Type 1 diabetes in mice, demonstrating that the combined transplantation of blood-forming stem cells and pancreatic islet cells from an immunologically mismatched donor can completely prevent or fully reverse the disease. This revolutionary approach, which cultivates a hybrid immune system within the recipient, offers unprecedented hope for millions worldwide affected by this chronic autoimmune condition. The study, published online on November 18 in the Journal of Clinical Investigation, builds upon years of foundational research in stem cell biology and immunology, presenting a potential paradigm shift in the management of autoimmune disorders.
A Novel Approach to Autoimmune Disease: Engineering a Tolerant Immune System
Type 1 diabetes is characterized by the immune system’s misguided assault on the body’s own insulin-producing beta cells within the pancreatic islets. This destruction leads to a profound deficiency in insulin, a hormone essential for regulating blood sugar levels, necessitating lifelong insulin therapy and posing significant risks of long-term complications. The Stanford team’s innovative strategy directly addresses this fundamental pathology by creating a unique immunological environment.
In their research, mice received both blood-forming stem cells and pancreatic islet cells from donors with different immune profiles. Crucially, this dual transplantation, coupled with a carefully modulated pre-transplant regimen, resulted in the development of a hybrid immune system. This hybrid system seamlessly integrated cells from both the donor and the recipient, fostering a state of mutual tolerance. This meant the transplanted islets were not recognized as foreign invaders by the recipient’s immune system, and conversely, the donor-derived immune cells did not launch an attack against the recipient’s healthy tissues, including the newly engrafted islets.
The results were striking. None of the mice in the study developed graft-versus-host disease (GVHD), a common and potentially life-threatening complication of stem cell transplantation where the donor immune cells attack the recipient’s body. Furthermore, the destruction of islet cells by the animals’ original immune system ceased. Post-transplant, the mice were able to maintain normal blood sugar levels without the need for immunosuppressive drugs or exogenous insulin for the entire six-month study period. This sustained restoration of glycemic control in a disease that is typically lifelong and progressive marks a significant advancement.
Building on Decades of Research: The Evolution of Stem Cell Transplantation
The current breakthrough is the culmination of extensive work by a dedicated team of researchers at Stanford, led by Seung K. Kim, MD, PhD, the KM Mulberry Professor and a leading figure in developmental biology, gerontology, endocrinology, and metabolism. Dr. Kim, who also directs the Stanford Diabetes Research Center and the Northern California Breakthrough T1D Center of Excellence, highlighted the significance of the findings. "The possibility of translating these findings into humans is very exciting," he stated. "The key steps in our study — which result in animals with a hybrid immune system containing cells from both the donor and the recipient — are already being used in the clinic for other conditions. We believe this approach will be transformative for people with Type 1 diabetes or other autoimmune diseases, as well as for those who need solid organ transplants."
This latest study significantly advances previous work conducted by Dr. Kim and his collaborators in 2022. In that earlier research, diabetes was experimentally induced in mice by using toxins to eliminate their insulin-producing cells. Following a pre-transplant preparation involving immune-targeting antibodies and low-dose radiation, the mice received transplants of blood stem cells and islet cells from an unrelated donor, successfully restoring blood sugar control. However, that model presented a less complex immunological challenge compared to naturally occurring autoimmune diabetes.
The new research tackled a far more formidable hurdle: preventing or curing diabetes driven by the body’s own spontaneous immune attack on its islet cells, mirroring the pathogenesis of human Type 1 diabetes. In this scenario, transplanted islets face a dual threat: they are inherently recognized as foreign by the recipient’s immune system, and that same immune system is already predisposed to destroy islet cells regardless of their origin.
"Just like in human Type 1 diabetes, the diabetes that occurs in these mice results from an immune system that spontaneously attacks the insulin-producing beta cells in pancreatic islets," explained Dr. Kim. "We need to not only replace the islets that have been lost but also reset the recipient’s immune system to prevent ongoing islet cell destruction. Creating a hybrid immune system accomplishes both goals."
A Refined Protocol: The Role of Immunomodulatory Drugs
A significant challenge in preparing mice with autoimmune diabetes for blood stem cell transplantation lies in their inherent immune system’s heightened reactivity. The Stanford team devised a relatively straightforward solution to overcome this obstacle. By incorporating a medication commonly used to treat autoimmune diseases into the pre-transplant regimen established in their 2022 study, they achieved remarkable success.
This adjusted protocol, which included immune-targeting antibodies, low-dose radiation, and the additional autoimmune medication, followed by the transplantation of blood stem cells, led to the development of a hybrid immune system in the mice. In 19 out of 19 cases, these mice did not develop Type 1 diabetes. Furthermore, in a separate cohort of mice that already had established Type 1 diabetes, a combined blood stem cell and islet cell transplant resulted in a complete cure in all nine animals.
The feasibility of translating this strategy to human trials is bolstered by the fact that the antibodies, drugs, and low-dose radiation employed in the mouse model are already standard components of clinical practice for blood stem cell transplantation. This existing clinical familiarity significantly de-risks the path towards human application.
From Kidney Tolerance to Hybrid Immunity: A Legacy of Innovation
The scientific underpinnings of this groundbreaking work trace back to pioneering research by the late Samuel Strober, MD, PhD, a distinguished professor of immunology and rheumatology at Stanford, and his colleagues, including study co-author Judith Shizuru, MD, PhD, a professor of medicine. Their earlier investigations demonstrated that bone marrow transplants from partially immunologically matched human donors could induce a hybrid immune system in recipients, enabling long-term acceptance of kidney transplants from the same donor. In some patients, this led to stable kidney function for decades without the need for continuous immunosuppressive drugs, a testament to the power of immune tolerance induction.
Blood stem cell transplantation is an established treatment for hematologic malignancies like leukemia and lymphoma. However, these cancer treatments typically involve high-dose chemotherapy and radiation to eradicate the patient’s existing blood and immune system, often leading to severe side effects. Dr. Shizuru and her team have been instrumental in developing safer, less intensive pre-treatment protocols for individuals with non-cancerous conditions, such as Type 1 diabetes. Their methods aim to reduce bone marrow activity just enough to allow donor blood stem cells to engraft and flourish, thereby minimizing toxicity.
"Based on many years of basic research by us and others, we know that blood stem cell transplants could also be beneficial for a wide range of autoimmune diseases," stated Dr. Shizuru. "The challenge has been to devise a more benign pre-treatment process, diminishing risk to the point that patients suffering from an autoimmune deficiency that may not be immediately life-threatening would feel comfortable undergoing the treatment."
The current study provides a critical piece of this puzzle. "Now we know that the donated blood stem cells re-educate the recipient animal’s immune system to not only accept the donated islets, but also not attack its healthy tissues, including islets," Dr. Kim elaborated. "In turn, the donated blood stem cells and the immune system they produce learn to not attack the recipient’s tissues, and graft-versus-host disease can be avoided." This bidirectional tolerance is the cornerstone of their success.
Addressing Future Hurdles: The Path to Human Application
Despite the highly encouraging results in mice, significant obstacles remain before this innovative strategy can be widely applied to treat Type 1 diabetes in humans. A primary challenge is the current reliance on pancreatic islets obtained solely from deceased donors. Furthermore, the blood stem cells and the islet cells must originate from the same donor to establish the necessary immunological compatibility. The limited number of islet cells typically recovered from a single donor also raises questions about whether it would consistently be sufficient to reverse established Type 1 diabetes in human patients.
The Stanford scientists are actively exploring avenues to surmount these limitations. Promising strategies include the laboratory production of large quantities of functional islet cells from pluripotent human stem cells. Additionally, researchers are investigating methods to enhance the survival and efficiency of transplanted donor islets post-transplantation.
Beyond Type 1 diabetes, Dr. Kim, Dr. Shizuru, and their colleagues believe that their gentle pre-conditioning strategy holds immense promise for treating a broad spectrum of autoimmune diseases. Conditions such as rheumatoid arthritis and lupus, as well as non-cancerous blood disorders like sickle cell anemia, could potentially benefit from this approach, especially given the harshness of current blood stem cell transplant methods for these diseases. Moreover, the technique could revolutionize solid organ transplantation, particularly in cases involving mismatched donors.
"The ability to reset the immune system safely to permit durable organ replacement could rapidly lead to great medical advances," Dr. Kim concluded, underscoring the far-reaching implications of their work.
The research was supported by substantial funding from the National Institutes of Health, including grants T32 GM736543, R01 DK107507, R01 DK108817, U01 DK123743, P30 DK116074, and LAUNCH 1TL1DK139565-0. Additional support was provided by the Breakthrough T1D Northern California Center of Excellence, Stanford Bio-X, the Reid Family, the H.L. Snyder Foundation and Elser Trust, the VPUE Research Fellowship at Stanford, and the Stanford Diabetes Research Center. This multidisciplinary and well-supported effort underscores the significant investment and commitment to finding transformative treatments for debilitating diseases.
